Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | How CAR-T will impact the future of myeloma treatment

Nico Gagelmann • 15 Feb 2024
CAR-T Meeting 2024
Multiple Myeloma CAR-T
CARTITUDE-5

In this video, Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly comments on how CAR T-cell therapy will impact the treatment of multiple myeloma (MM) in the future. Dr Gagelmann is confident that this therapeutic option will move to the frontline setting and highlights that the newly developed MyCARe model may help predict which patients are suitable candidates for receiving CAR-T in the frontline. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nico Gagelmann

1:22
The role of splenic irradiation in transplant for patients with myelofibrosis
Nico Gagelmann • 15 Feb 2024
1:41
Predicting outcomes in patients with R/R MM undergoing CAR T-cell therapy: the MyCARe model
Nico Gagelmann • 15 Feb 2024
2:03
Looking to the future in the field of transplantation
Nico Gagelmann • 9 Dec 2023
1:45
Comparing salvage transplantion to CAR T-cell therapy for treating relapsed multiple myeloma
Nico Gagelmann • 9 Dec 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals